Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 10/20 | 0.64 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.48 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.48 |
| ▸ | CDK2 | P24941 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21967196 | 0.97 | FLT3 (0.59) | FLT3YTHDC1CYP1A2PDGFRACCNE1 | |
| SCHEMBL21967885 | 0.92 | FLT3 (0.74) | FLT3YTHDC1PDGFRACCNE1CDK2 | |
| SCHEMBL21967753 | 0.91 | FLT3 (0.65) | FLT3YTHDC1PDGFRACCNE1CDK2 | |
| SCHEMBL21967445 | 0.90 | FLT3 (0.64) | FLT3YTHDC1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL21967507 | 0.90 | FLT3 (0.64) | FLT3YTHDC1PDGFRACCNE1CDK2 | |
| SCHEMBL21967560 | 0.90 | YTHDC1 (0.71) | FLT3YTHDC1CYP1A2PDGFRACCNE1 | |
| SCHEMBL21967668 | 0.89 | FLT3 (0.59) | FLT3YTHDC1CYP1A2PDGFRACCNE1 | |
| SCHEMBL21967579 | 0.89 | FLT3 (0.69) | FLT3YTHDC1CCNE1CDK2NPC1 | |
| SCHEMBL21967854 | 0.88 | YTHDC1 (0.56) | FLT3YTHDC1CYP1A2PDGFRACCNE1 | |
| SCHEMBL21967801 | 0.88 | FLT3 (0.58) | FLT3YTHDC1CYP1A2PDGFRACCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10662194-B2 | Substituted 6-anilino-9-heterocyclylpurine derivatives for inhibition of plant stress | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2020-05-26 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10662194-B2 | Substituted 6-anilino-9-heterocyclylpurine derivatives for inhibition of plant stress | TPMT, MTAP, ATIC | FLT3 2877/4885YTHDC1 384/4885CYP1A2 220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.